Zeprumetostat

Phase 2Small molecule

SSun Yat-sen University

Zeprumetostat is one of 101 small molecule programs targeting Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaNot yet recruiting

Peripheral T-Cell Lymphoma (PTCL)Not yet recruiting

Bladder Urothelial CarcinomaRecruiting

LymphomaNot yet recruiting

PTCLRecruiting

LeukemiaPhase 1

Not yet recruiting

Peripheral T-Cell Lymphoma (PTCL)Preclinical

Not yet recruiting

Bladder Urothelial CarcinomaPhase 2

Recruiting

LymphomaPhase 2

Not yet recruiting

PTCLPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zeprumetostat

SSun Yat-sen University

Phase 2

2 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Leukemia

NCT07692529

Q1 2029

Phase 2Recruiting

Bladder Urothelial Carcinoma

NCT07717242

Q3 2029

PreclinicalNot yet recruiting

Peripheral T-Cell Lymphoma (PTCL)

NCT07706959

Phase 2Recruiting

PTCL

NCT07372352

Q1 2030

Phase 1/2Not yet recruiting

Lymphoma

NCT07339527

Clinical

Trials by Indication[1]

Lymphoma2 trials

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07339527·60 enrolled

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Recruiting·TTreeline Biosciences, Inc.·Phase 1·NCT07082803·180 enrolled

Not yet recruiting·RRuijin Hospital·Preclinical·NCT07706959·108 enrolled

Leukemia1 trial

A Prospective and Exploratory Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07692529·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Zeprumetostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zeprumetostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zeprumetostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Zeprumetostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2029

Q3 2029

Q1 2030

Trials by Indication[1]

Lymphoma2 trials

PTCL1 trial

Bladder Urothelial Carcinoma1 trial

Peripheral T-cell Lymphoma (PTCL)1 trial

Leukemia1 trial

References

Drug Info

Quick Facts

Related News